Skip to content
value.today

Eli Lilly and Company vs Roche Holding AG

Add a company

Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.

In short

  • Eli Lilly and Company is the larger company by market value: $1.20 T against $370.3 B for Roche Holding AG, 3.2 times as much (market caps of Oct 26, 2026 for Eli Lilly and Company and Aug 1, 2026 for Roche Holding AG). Roche Holding AG's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.
  • Roche Holding AG had more revenue: $67.0 B in the year to December 2023 against $65.2 B for Eli Lilly and Company in the year to December 2025.
  • Eli Lilly and Company earned more: net income of $20.6 B against $12.7 B for Roche Holding AG.
  • Eli Lilly and Company keeps more of each dollar of sales: a net margin of 31.7% against 19.0% for Roche Holding AG.
  • Roche Holding AG employs more people: 103,613 against 50,000 at Eli Lilly and Company. Each employee brings in about $1,303,580 of revenue at Eli Lilly and Company and $646,705 at Roche Holding AG.
  • On price to earnings, Eli Lilly and Company trades at 43.4× and Roche Holding AG at 29.1×: investors pay more for each dollar of Eli Lilly and Company's profit.

Market value, the same start = 100

From Jan 2020: how each one's value moved, whatever its size.

02344677019352020202120222023202420252026Eli Lilly and Company 935Roche Holding AG 132

Revenue by fiscal year

US$ billions, as reported in each year's annual results.

$0B$16B$33B$49B$65B201720182019202020212022202320242025Eli Lilly and Company $65B

Side by side

Side-by-side comparison; ▲ marks the best value of a measure where higher or lower is better
MeasureEli Lilly and Company
LLY · #13 in the world
Roche Holding AG
ROG.SW · #38 in the world
Profile
Country🇺🇸 USA🇨🇭 Switzerland
SectorHealthcareHealthcare
IndustryPharmaceuticalPharmaceutical
Founded18761896
Size
Market cap$1.20 T$370.3 B
Revenue$65.2 B$67.0 B
Net income$20.6 B▲ best$12.7 B
Employees50,000103,613
Valuation
P/E ratio43.4×29.1×
Price to sales13.9×5.5×
Price to book45.1×10.0×
Profitability
Gross margin83.0%—
Net margin31.7%—
Return on equity101.2%—
Growth
Revenue growth44.7%—
Revenue growth, 3 years a year31.7%—
Earnings per share growth96.0%—
Financial strength
Debt to equity1.5×—
Shareholder returns
Dividend yield0.5%—
Shareholder yield0.8%—
Strength scores
Piotroski F-score7 of 9—
Altman Z-score zone——
Data as ofMarket cap Oct 2026; ratios FY2025Market cap Aug 2026

▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither

Questions and answers#

Which is bigger, Eli Lilly and Company or Roche Holding AG?

Eli Lilly and Company is the larger company by market value: $1.20 T against $370.3 B for Roche Holding AG, 3.2 times as much (market caps of Oct 26, 2026 for Eli Lilly and Company and Aug 1, 2026 for Roche Holding AG). Roche Holding AG's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.

Which makes more money, Eli Lilly and Company or Roche Holding AG?

Roche Holding AG had more revenue: $67.0 B in the year to December 2023 against $65.2 B for Eli Lilly and Company in the year to December 2025. Eli Lilly and Company earned more: net income of $20.6 B against $12.7 B for Roche Holding AG.

Which is more profitable, Eli Lilly and Company or Roche Holding AG?

Eli Lilly and Company keeps more of each dollar of sales: a net margin of 31.7% against 19.0% for Roche Holding AG.

Which has more employees, Eli Lilly and Company or Roche Holding AG?

Roche Holding AG employs more people: 103,613 against 50,000 at Eli Lilly and Company. Each employee brings in about $1,303,580 of revenue at Eli Lilly and Company and $646,705 at Roche Holding AG.

Is Eli Lilly and Company cheaper than Roche Holding AG?

On price to earnings, Eli Lilly and Company trades at 43.4× and Roche Holding AG at 29.1×: investors pay more for each dollar of Eli Lilly and Company's profit. A lower multiple is not by itself a better buy: it also reflects expected growth, risk and accounting.

Sources#

Every figure on this page comes from these, with the date shown next to it.